Unlike anything available on the market today, the Gii platform is scientifically advanced, technically flexible, and ready to be designed for any specification. We partner with companies to co-develop and customise the platform for their requirements, giving a powerful head start towards building the next-generation diagnostic or sensing solution.
Detect multiple biomarkers simultaneously, whether it is antibodies, proteins, enzymes, ions, small molecules, and nucleic acids.
Achieve quantitative results with lab-grade accuracy in 5 to 15 minutes.
Reduce workflow complexity by consolidating multiple tests into a single, scalable solution.
Gii offers a high electrochemical active surface area with intrinsic antifouling properties that enable fast, accurate response.
Compatible with a wide range of analytes, including antibodies, aptamers and enzymes.
Manufactured using a sustainable, low-energy process with consistent, scalable production.
A modular reader with Bluetooth, WiFi or wired output, adaptable for digital diagnostics.
Compatible with microfluidics and low sample volumes, allowing easy assay integration.
Flexible interface design and data handling, aligned to ISO 13485 development pathways.
75 plus assays in the pipeline across human health, veterinary, water, soil and food applications.
Platform performance benchmarked against ELISA, PCR and LAMP with faster results at lower cost.
Supported by a robust IP portfolio and a long-term commercial partnership model including licensing, royalty or unit-based options.
iGii’s platform makes next-generation sensing a real, scalable commercial opportunity. By combining validated technology, industry-specific applications, and breakthrough material science, we help businesses bring high-performance, cost-effective, and future-proofed sensing solutions to market faster with less risk.